Hlib Chabaniuk

Pacific Biosciences of California explores challenges in operationalizing long-read sequencing in clinical environments

Pacific Biosciences of California explores challenges in operationalizing long-read sequencing in clinical environments
PacBio spotlights clinical lab hurdles

Pacific Biosciences of California is drawing attention to the practical challenges faced by clinical laboratories as they consider adopting long-read sequencing technology.

The company points to validation processes and operational scalability as key concerns, emphasizing the need for real-world evidence, workflow integration, and assay consolidation. Pacific Biosciences of California's latest blog post examines how clinical labs can streamline implementation for advanced sequencing while maintaining accuracy and efficiency.

Pacific Biosciences of California recently attracted significant attention at ESHG2026 with well-attended sessions and booth events. The company has also introduced its Ampli-Fi workflow, enabling clinical labs to perform HiFi sequencing with lower DNA input requirements. These initiatives reflect Pacific Biosciences’ ongoing engagement with the clinical sequencing community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.